These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 11043851)

  • 1. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells.
    Flieger D; Kufer P; Beier I; Sauerbruch T; Schmidt-Wolf IG
    Cancer Immunol Immunother; 2000 Oct; 49(8):441-8. PubMed ID: 11043851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A bispecific antibody enhances cytokine-induced killer-mediated cytolysis of autologous acute myeloid leukemia cells.
    Kaneko T; Fusauchi Y; Kakui Y; Masuda M; Akahoshi M; Teramura M; Motoji T; Okumura K; Mizoguchi H; Oshimi K
    Blood; 1993 Mar; 81(5):1333-41. PubMed ID: 8095165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approaches to lung cancer treatment using the CD3 x EGP-2-directed bispecific monoclonal antibody BIS-1.
    Kroesen BJ; Nieken J; Sleijfer DT; Molema G; de Vries EG; Groen HJ; Helfrich W; The TH; Mulder NH; de Leij L
    Cancer Immunol Immunother; 1997; 45(3-4):203-6. PubMed ID: 9435874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The regulation of phenotype and function of human liver CD3+/CD56+ lymphocytes, and cells that also co-express CD8 by IL-2, IL-12 and anti-CD3 monoclonal antibody.
    Jin Y; Fuller L; Carreno M; Esquenazi V; Tzakis AG; Miller J
    Hum Immunol; 1998 Jun; 59(6):352-62. PubMed ID: 9634197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 x CD19.
    Klein SC; Boer LH; de Weger RA; de Gast GC; Bast EJ
    Scand J Immunol; 1997 Nov; 46(5):452-8. PubMed ID: 9393627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.
    Ferrari F; Bellone S; Black J; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Menderes G; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    J Exp Clin Cancer Res; 2015 Oct; 34():123. PubMed ID: 26474755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
    Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110.
    Petsch S; Gires O; Rüttinger D; Denzel S; Lippold S; Baeuerle PA; Wolf A
    MAbs; 2011; 3(1):31-7. PubMed ID: 21107020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
    English DP; Bellone S; Schwab CL; Roque DM; Lopez S; Bortolomai I; Cocco E; Bonazzoli E; Chatterjee S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Cancer; 2015 Feb; 121(3):403-12. PubMed ID: 25251053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
    Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
    Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells.
    Kaneko T; Fusauch Y; Kakui Y; Okumura K; Mizoguchi H; Oshimi K
    Leuk Lymphoma; 1994 Jul; 14(3-4):219-29. PubMed ID: 7950910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2-bispecific antibody is enhanced in combination with interferon-α.
    Rossi EA; Rossi DL; Cardillo TM; Chang CH; Goldenberg DM
    Mol Cancer Ther; 2014 Oct; 13(10):2341-51. PubMed ID: 25053819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab.
    Kornacker M; Verneris M; Kornacker B; Ganten T; Scheffold C; Negrin R
    Cytotherapy; 2006; 8(1):13-23. PubMed ID: 16627341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression.
    Zhang P; Shi B; Gao H; Jiang H; Kong J; Yan J; Pan X; Li K; Zhang P; Yao M; Yang S; Gu J; Wang H; Li Z
    Cancer Immunol Immunother; 2014 Feb; 63(2):121-32. PubMed ID: 24177984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.
    Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG
    J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo.
    Dettmar K; Seitz-Merwald I; Lindemann C; Schroeder P; Seimetz D; Atz J
    Clin Transl Oncol; 2012 May; 14(5):376-81. PubMed ID: 22551544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.
    Flieger D; Hoff AS; Sauerbruch T; Schmidt-Wolf IG
    Clin Exp Immunol; 2001 Jan; 123(1):9-14. PubMed ID: 11167991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thymoglobulin efficiently expands cytokine-induced killer cells in a clinical-grade culture protocol].
    Chen W; Lin D; Jiang Z; Yang Z; Song S; Zhou J; Zhou L; Sun Y; Yu H; Ma D
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):681-5, 690. PubMed ID: 25001928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells.
    Carlens S; Gilljam M; Chambers BJ; Aschan J; Guven H; Ljunggren HG; Christensson B; Dilber MS
    Hum Immunol; 2001 Oct; 62(10):1092-8. PubMed ID: 11600215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.